Chapter 21: Biotechnology

Microorganisms serve as biological factories for pharmaceutical production, with genetically engineered bacteria synthesizing critical medications including insulin and tissue plasminogen activator. Beyond medicine, microbes function in biological pest management and disease suppression, while specialized bacteria remediate environmental contamination by degrading petroleum and other hazardous pollutants. The chapter then shifts to animal biotechnology, detailing strategies for creating transgenic organisms through gene insertion and modification. Gene knockout and knockin techniques enable the development of animal models that replicate human diseases, particularly in mice used for disease research. Transgenic livestock become bioreactors themselves, producing human proteins in milk through molecular pharming—a technique linking human genes to lactation-specific regulatory sequences. Reproductive cloning via nuclear transfer technology is explored through the landmark case of Dolly the sheep, while acknowledging biological obstacles including telomere degradation and aberrant gene expression. The chapter then introduces stem cell science, distinguishing between totipotent, pluripotent, multipotent, and unipotent classifications. Embryonic stem cells and embryonic germ cells demonstrate considerable differentiation capacity for regenerative applications, though induced pluripotent stem cells represent a transformative breakthrough, allowing researchers to reprogram differentiated adult cells without requiring embryonic tissue. Plant biotechnology receives substantial attention, with discussion of herbicide-resistant and pest-resistant crops created through Agrobacterium-mediated gene transfer, biolistic methods, and electroporation. Engineered plants now produce extended shelf-life characteristics, enhanced nutritional profiles, and even therapeutic proteins and biodegradable polymers. The chapter concludes by addressing regulatory frameworks, environmental implications, and public health considerations surrounding genetically modified organisms, emphasizing the necessity for transparent governance and evidence-based assessment of biotechnological innovations.